Update in Glycoprotein IIb/IIIa Receptor Antagonist Clopidogrel: Use in Cerebrovascular Accidents

Acute ischemic stroke is the most common manifestation of cerebrovascular disease, which ranks the first to make an adult become bedridden and/or out of productive life. Antiplatelet therapy has long been demonstrated to alleviate the risks of recurrent untoward events, especially in the setting of secondary prevention. In the last decade it has been proved that dual antiplatelet therapy (DAPT) appears to be more efficacious than monotherapy with aspirin. Clopidogrel (CLP) -an irreversible inhibitor of the platelet P2Y12 adenosine diphosphate receptor- is licensed in adults for the prevention of atherothrombotic events in patients suffering from MI, ischemic stroke (from 7 days to 6 months) or peripheral arterial disease. The recommended dose is 75 mg as a single daily dose, taken with or without food. This review is designed to encompass use of the agent comprehensively and delineates a frame in which clinicians can view as a guide in their routine clinical practice. 

[1]  Kortaro Tanaka,et al.  Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial , 2019, The Lancet Neurology.

[2]  J. Airaksinen,et al.  Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting. , 2019, The Annals of thoracic surgery.

[3]  Huisheng Chen,et al.  Antiplatelet vs. R-tPA for acute mild ischemic stroke: A prospective, random, and open label multi-center study , 2019, International journal of stroke : official journal of the International Stroke Society.

[4]  Zhangui Tang,et al.  Cangrelor or Clopidogrel in Patients with Type 2 Diabetes Mellitus Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Controlled Trials , 2019, Diabetes Therapy.

[5]  H. Krumholz,et al.  Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation , 2019, BMJ Open.

[6]  R. Conwit,et al.  Clopidogrel and Aspirin in Acute Ischemic Stroke and High‐Risk TIA , 2018, The New England journal of medicine.

[7]  H. H. Jensen,et al.  Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial , 2017, The Lancet.

[8]  J. Gutierrez,et al.  Letter re: Risks and benefits of clopidogrel–aspirin in minor stroke or TIA: Time course analysis of CHANCE , 2017, Neurology.

[9]  Rustam Al-Shahi Salman,et al.  Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): a randomised, open-label, phase 3 trial , 2016, The Lancet.

[10]  Y. Xing,et al.  Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis , 2016, BMJ Open.

[11]  Marta a. Miyares,et al.  Dual antiplatelet therapy with clopidogrel and aspirin after ischemic stroke: A review of the evidence. , 2015, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[12]  R. Akdemir,et al.  Acute Coronary Syndrome During Pregnancy: A Case Report and Literature Review , 2014, Turkish journal of emergency medicine.

[13]  C. Reilly,et al.  Successful gestation and delivery using clopidogrel for secondary stroke prophylaxis: a case report and literature review , 2014, Archives of Gynecology and Obstetrics.

[14]  Liping Liu,et al.  Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. , 2013, The New England journal of medicine.

[15]  C. Coffey,et al.  Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. , 2012, The New England journal of medicine.

[16]  E. Topol,et al.  Dual or Mono Antiplatelet Therapy for Patients With Acute Ischemic Stroke or Transient Ischemic Attack: Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2012, Stroke.

[17]  Y. Dundar,et al.  Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. , 2011, Health technology assessment.

[18]  P. Gorelick,et al.  Aspirin Plus Dipyridamole Versus Aspirin for Prevention of Vascular Events After Stroke or TIA: A Meta-Analysis , 2008, Stroke.

[19]  S. Gutnikov,et al.  Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison , 2007, The Lancet.

[20]  A. Algra,et al.  Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. , 2007, The Cochrane database of systematic reviews.

[21]  Alan D. Lopez,et al.  Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data , 2006, The Lancet.

[22]  A. Brennan,et al.  Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK , 2005, Current medical research and opinion.

[23]  S. Palmer,et al.  Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation. , 2004, Health technology assessment.

[24]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[25]  Peter Sandercock,et al.  The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke , 1997, The Lancet.

[26]  C. Pop,et al.  Anticoagulation in Acute Coronary Syndrome: Review of Major Therapeutic Advances , 2019, American journal of therapeutics.

[27]  A. Mazza,et al.  Clopidogrel treatment during pregnancy: a case report and a review of literature. , 2011, Internal medicine.

[28]  G. Moneta.  Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events , 2008 .